DE60108710D1 - Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel - Google Patents

Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel

Info

Publication number
DE60108710D1
DE60108710D1 DE60108710T DE60108710T DE60108710D1 DE 60108710 D1 DE60108710 D1 DE 60108710D1 DE 60108710 T DE60108710 T DE 60108710T DE 60108710 T DE60108710 T DE 60108710T DE 60108710 D1 DE60108710 D1 DE 60108710D1
Authority
DE
Germany
Prior art keywords
testosterone
treatment
containing composition
estrogen agonist
decreasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60108710T
Other languages
English (en)
Other versions
DE60108710T2 (de
Inventor
David Burton Mclean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60108710D1 publication Critical patent/DE60108710D1/de
Application granted granted Critical
Publication of DE60108710T2 publication Critical patent/DE60108710T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60108710T 2000-11-30 2001-11-08 Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel Expired - Fee Related DE60108710T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25007100P 2000-11-30 2000-11-30
US250071P 2000-11-30

Publications (2)

Publication Number Publication Date
DE60108710D1 true DE60108710D1 (de) 2005-03-10
DE60108710T2 DE60108710T2 (de) 2006-05-04

Family

ID=22946195

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60108710T Expired - Fee Related DE60108710T2 (de) 2000-11-30 2001-11-08 Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel

Country Status (15)

Country Link
US (2) US20020115676A1 (de)
EP (1) EP1210951B1 (de)
JP (1) JP2002193809A (de)
KR (1) KR20020042505A (de)
AT (1) ATE288303T1 (de)
AU (1) AU779964B2 (de)
CA (1) CA2363935A1 (de)
DE (1) DE60108710T2 (de)
DK (1) DK1210951T3 (de)
ES (1) ES2233570T3 (de)
HU (1) HUP0105201A3 (de)
IL (1) IL146701A0 (de)
NZ (1) NZ515822A (de)
PT (1) PT1210951E (de)
ZA (1) ZA200109836B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
DE60305068T2 (de) * 2002-12-18 2007-01-11 Laboratoires Besins International Behandlung von mastalgie mit 4-hydroxy-tamoxifen
TWI330529B (en) * 2003-01-13 2010-09-21 Horphag Res Luxembourg Holding Sa A preparation for improving sperm quality or fertility,a kit comprising the same and uses thereof
DK1620140T3 (da) 2003-05-05 2013-12-09 Univ Ben Gurion Injicerbare tværbundne polymere præparater samt deres anvendelse
PT1694319E (pt) * 2003-12-15 2008-10-24 Besins Int Lab Utilização de 4-hidroxi-tamoxifeno na preparação de um medicamento para o tratamento da ginecomastia
EP1550440A1 (de) * 2003-12-15 2005-07-06 Laboratoires Besins International Verwendung von 4-hydroxytamoxifen zur Herstellung eines Arzneimittels zur Behandlung von Gynäkomastie
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
WO2005066337A2 (en) * 2004-01-09 2005-07-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
EP2307026B1 (de) 2008-07-04 2016-04-13 The Heart Research Institute Limited Verwendung von androgenen zur gefässregeneration und endothelreparatur
KR102335267B1 (ko) * 2017-03-16 2021-12-06 주식회사 자연과학기술 무지개송어 정소로부터 테스토스테론의 추출방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US585905A (en) * 1897-07-06 Frank bonileor
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata

Also Published As

Publication number Publication date
DK1210951T3 (da) 2005-03-29
ES2233570T3 (es) 2005-06-16
EP1210951A2 (de) 2002-06-05
US20020115676A1 (en) 2002-08-22
HU0105201D0 (en) 2002-01-28
KR20020042505A (ko) 2002-06-05
HUP0105201A2 (hu) 2002-12-28
HUP0105201A3 (en) 2004-04-28
EP1210951B1 (de) 2005-02-02
AU9516501A (en) 2002-06-06
CA2363935A1 (en) 2002-05-30
EP1210951A3 (de) 2003-09-24
JP2002193809A (ja) 2002-07-10
IL146701A0 (en) 2002-07-25
NZ515822A (en) 2003-05-30
PT1210951E (pt) 2005-04-29
ZA200109836B (en) 2003-05-29
ATE288303T1 (de) 2005-02-15
AU779964B2 (en) 2005-02-24
US20050288325A1 (en) 2005-12-29
DE60108710T2 (de) 2006-05-04

Similar Documents

Publication Publication Date Title
DE60108710D1 (de) Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
EE200300440A (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks
DE69912972D1 (de) Antibiotische zusammensetzungen zur behandlung des auges
GT200300040A (es) Composicion de ziprasidona y controles sinteticos
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE69941280D1 (de) Vorrichtung zur Behandlung von Stenosen an Verzweigungen
PT1199069E (pt) Utilização de um agonista/antagonista de estrogénio para melhoramento ou manutenção da saúde urogenital
UY26970A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gaba, para el tratamiento de trastornos cognitivos
EP1192945A3 (de) Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung von Osteoarthritis
ATE326842T1 (de) Zusammensetzung zur saatgutbehandlung
EP1465968A4 (de) Verfahren zur behandlung von dämpferkondensat
DE60037505D1 (de) Elektronen emittierende vorrichtung und diese vorrichtung verwendendes anzeigegerät
DE69913334T2 (de) Vorrichtung zur orthodontischen behandlung
GB9918429D0 (en) Organic compounds
AU1604001A (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
DE60129032D1 (de) Creatinester-pronutrient-verbindungen und formulierungen
SE0302361D0 (sv) Inhibering av upptagning av monoamin
ATE250580T1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
ATE374612T1 (de) Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose
DE69934684D1 (de) Vorrichtung zur gasbehandlung
AU2002350362A8 (en) Use of an anti-microtubule agent for the treatment of uveitis
HU9903222D0 (en) Produce for plugger remover of tobaccoproducts apparatus and the apparatus which work with this produce
ATE257822T1 (de) Aminoiminochinon und aminochinon alkaloid verbindungen als caspase inhibitoren
DE60024420D1 (de) Vorrichtung zur verhinderung des peitschentriebeffektes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee